Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
Abstract Bosutinib, a BCR-ABL1 tyrosine kinase inhibitor (TKI), has been available for several years as a treatment for chronic-, accelerated-, and blast-phase chronic myeloid leukemia (CML), for patients with resistance or intolerance to prior therapy. In 2017, the BFORE trial demonstrated efficacy...
Main Authors: | Jorge E. Cortes, Jane F. Apperley, Daniel J. DeAngelo, Michael W. Deininger, Vamsi K. Kota, Philippe Rousselot, Carlo Gambacorti-Passerini |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-12-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13045-018-0685-2 |
Similar Items
-
Bosutinib in chronic myeloid leukemia: patient selection and perspectives
by: Isfort S, et al.
Published: (2018-04-01) -
Clinical Experience and Perspectives of Bosutinib Use in Patients with Chronic Myeloid Leukemia
by: VA Shuvaev, et al.
Published: (2018-10-01) -
Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia
by: Akiko Mita, et al.
Published: (2018-04-01) -
High‐grade B‐cell lymphoma developed during the treatment of chronic myeloid leukemia with bosutinib
by: Teruhito Takakuwa, et al.
Published: (2021-03-01) -
Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
by: Mario Tiribelli, et al.
Published: (2019-08-01)